Contineum Therapeutics (CTNM) Change in Acquisitions & Divestments (2023 - 2026)

Contineum Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $58.1 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 19.46% year-over-year to $58.1 million in Q1 2026; TTM through Mar 2026 was $168.5 million, a 1.32% increase from a year earlier, with the FY2025 full-year figure at $159.0 million, up 1.18% from the prior year.
• Change in Acquisitions & Divestments rose to $58.1 million in Q1 2026 per CTNM's latest filing, from $37.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $58.1 million in Q1 2026 and bottomed at $12.6 million in Q3 2023.
• The 4-year median for Change in Acquisitions & Divestments is $37.3 million (2025), against an average of $34.7 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 235.53% in 2024 and fell 20.35% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $31.3 million in 2023, then jumped by 44.03% to $45.1 million in 2024, then fell by 17.3% to $37.3 million in 2025, then jumped by 55.73% to $58.1 million in 2026.
• Per Business Quant, the three latest CTNM Change in Acquisitions & Divestments figures stand at $58.1 million (Q1 2026), $37.3 million (Q4 2025), and $33.7 million (Q3 2025).